Skip to content

REmote MOnitoring of paTiEnts witH pacEmaker or implAntable cardioverteR defibrillaTor

REmote MOnitoring of paTiEnts witH pacEmaker or implAntable cardioverteR defibrillaTor

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06173089
Acronym
REMOTE-HEART
Enrollment
800
Registered
2023-12-15
Start date
2023-01-30
Completion date
2025-08-30
Last updated
2023-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure

Keywords

remote monitoring, home monitoring, heart failure, cardiac resynchronization therapy, implantable cardioverter defibrillator

Brief summary

However, the current guidelines recommend the use of remote monitoring (RM) in patients with cardiac implantable electronic devices (CIED) to reduce inappropriate shocks or early detection of atrial fibrillation, data is incomprehensive on the effectiveness of decreasing heart failure events or mortality in patients with heart failure and reduced ejection fraction (HFrEF). The only randomized trial, which proved the efficacy of RM on mortality was the IN-TIME trial, which used a strict protocol for detection and intervention of the heart failure events. The primary aim of this study is to optimize the use of remote monitoring system in HFrEF patients already implanted an implantable cardiac defibrillator (ICD) or a cardiac resynchronization therapy (CRT). By creating a high-quality system with structured safety-net, which is able to use the data of remote monitoring messages and alerts of our patients, we can improve their outcome. The primary endpoint is the non-fatal heart failure event or all-cause mortality. Secondary outcomes include all-cause mortality, cardiovascular mortality, heart failure hospitalization, cardiovascular hospitalization, unscheduled visits, af burden, stroke, inappropriate shocks, quality of life, NYHA functional class. By using artificial intelligence-based methods, the optimal cut-off values of the previously, empirically used alert parameters will be validated or challenged. Additionally, cost-effectiveness to reduce the hospitalizations will be calculated. Due to this remote monitoring structured safety-net, these patients with severe heart failure can be treated more efficiently, safely and cost-effectively.

Interventions

DEVICERemote monitoring

Remote monitoring for patients with an ICD/CRT device

Sponsors

Semmelweis University Heart and Vascular Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

1. CRT-P/CRT-D patients with a feasible device for home monitoring 2. ICD (VVI/VDD/DDD) patients with a feasible device for home monitoring 3. SR/AFib 4. Transmission performance \>80% in the first 2 weeks with new device 5. Informed consent

Exclusion criteria

1. Life expectancy\<1 year 2. Unable to transmit data 3. Patient is unable to visit the physician/clinic in 12 hours when it is indicated by the alerts 4. Expected non-compliance 5. Pregnancy 6. Known drug, alcohol abuse 7. Participation in other study or HM system concept

Design outcomes

Primary

MeasureTime frame
The composite of all-cause mortality, heart failure events12 months

Secondary

MeasureTime frame
cardiovascular mortality12 months
cardiovascular hospitalization12 months
unscheduled visits12 months

Other

MeasureTime frame
Change in Kansas City Cardiomyopathy Questionnaire score12 months
change of symptoms (assessed by NYHA classification)12 months

Countries

Hungary

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026